Complement activation defects in pediatric oncology patients: hidden factors contributing to the increased risk of infection.

Completed

Conditions: Complement activation defects
10027665
10002252
risk of infection
10027655

Registration Number: NL-OMON37745

Lead Sponsor: Academisch Medisch Centrum

Brief Summary: Not available

Detailed Description: Not available

Recruitment & Eligibility

Status: Completed

Sex: Not specified

Target Recruitment: 160

Inclusion Criteria

All (newly) diagnosed pediatric oncology patients, irrespective of the tumor type or its treatment
Admittance for chemotherapy course as treatment of the malignancy
Admittance for treatment of a suspected or proven infection

Exclusion Criteria

Post-hoc exclusion may be applicable for the patients who are septic at the time of inclusion, because complement consumption may occur as a consequence of the overwhelming infection. On the other hand, complement defects may increase the risk of infections.

Study & Design

Study Type: Observational invasive

Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
<p>Complement activation defects (objective 1 & 2).</p><br>

Secondary Outcome Measures

Name	Time	Method
<p>Determination of the prevalence of the complement defects in complement<br /><br>activation in pediatric oncology patients in relation to the type of malignancy<br /><br>(leukemia, lymphoma, solid tumor), oncological treatment (chemotherapy,<br /><br>radiotherapy, surgery, or combinations hereof), potential loss or sequestration<br /><br>of complement factors [severity and duration of febrile neutropenia, proven<br /><br>infections, gastrointestinal complication, tumor lysis = estimated tumor mass]<br /><br>and potential lack of synthesis of complement factors [liver function, BM<br /><br>suppression]. </p><br>